
Claims



1. A compound of formula I or its pharmaceutically acceptable salts,




(I)

wherein, in the compound of formula I,

R^A is independently selected at each occurrence from-


and

, such that at least once it is selected as



Ring 'A' is selected from 3 to 6 membered carbocycle and 3 to 6 membered heterocycle containing 1 to 2 heteroatom(s) selected from N, S, and O, the ring 'A' may further be annulated with ~~substituted or unsubstituted~~ 3 to 6 membered carbocycle, ~~substituted or unsubstituted~~ 3 to 6 membered heterocycle containing 1 to 2 heteroatom(s) selected from N, S, and O, ~~substituted or unsubstituted~~ 6 membered aromatic carbocycle, or ~~substituted or unsubstituted~~ 5 to 6 membered aromatic heterocycle containing 1 to 2 heteroatom(s) selected from N, S, and O;

ring D is selected from ~~substituted or unsubstituted~~ 5 to 10 membered carbocycle~~s~~ optionally substituted with 1 to 2 substituents selected from the group consisting of oxo, halogen, C_{1-6} alkyl, C_{1-6} alkyl-O-, (C_{1-6} alkyl)(H)N-, and (C_{1-6} alkyl)$_2$N-, ~~substituted or unsubstituted~~ 6 membered aromatic

carbocycle optionally substituted with 1 to 2 substituents selected from the group consisting of halogen, nitro, cyano, hydroxy, C_{1-6} alkyl, perhalo C_{1-6} alkyl, C_{1-6} alkyl-O-, H_2N-, (C_{1-6} alkyl)(H)N-, (C_{1-6} alkyl)$_2$N-, (C_{1-6} alkyl)SO_2-, and $H_2NC(=O)$-, ~~substituted or unsubstituted~~ 5 to 10 membered heterocycles containing 1 to 3 heteroatom(s)/group(s) selected from N(R^{10}), $S(O)_p$, O, or C(=O), optionally substituted with 1 to 2 substituents selected from the group consisting of oxo, halogen, C_{1-6} alkyl, C_{1-6} alkyl-O-, (C_{1-6} alkyl)(H)N-, and (C_{1-6} alkyl)$_2$N-, and 5 to 6 membered ~~substituted or unsubstituted~~ aromatic heterocycle containing 1-2 heteroatom(s) selected from N, S, or O, optionally substituted with 1 to 2 substituents selected from the group consisting of halogen, nitro, cyano, hydroxy, C_{1-6} alkyl, perhalo C_{1-6} alkyl, C_{1-6} alkyl-O-, H_2N-, (C_{1-6} alkyl)(H)N-, (C_{1-6} alkyl)$_2$N-, and (C_{1-6} alkyl)-SO_2-;

Ring 'E' is 5 to 10 membered heterocycle, the ring 'E' may be monocyclic, fused bicyclic, bridged bicyclic, or spiro bicyclic;

R^1 is selected independently at each occurrence from the group consisting of halogen, ~~substituted or unsubstituted~~ C_{1-6} alkyl, and $R^{10}O$-, ~~$R^{10a}OC(=O)$-, and $(R^{10})(R^{11})NC(=O)$-~~; or two R^1s taken together may form an oxo (=O) group;

R^2 is selected independently at each occurrence from the group consisting of ~~substituted or unsubstituted~~ C_{1-6} alkyl, $R^{10a}C(=O)$-, ~~$R^{10a}SO_2$-~~, $R^{10a}OC(=O)$-, $R^{10}(R^{11})NC(=O)$-, $R^{10a}OC(=O)N(R^{11})C(R^a)(R^b)C(=O)$-, and $R^{10a}OC(=O)N(R^{11})C(R^a)(R^b)C(R^c)(R^d)C(=O)$-~~, $R^{10}(R^{11})NC(=O)N(R^{12})C(R^a)(R^b)C(=O)$-, $R^{10}(R^{11})NC(=O)N(R^{12})C(R^a)(R^b)C(R^c)(R^d)C(=O)$-, $R^{10a}SO_2N(R^{11})C(R^a)(R^b)C(=O)$-, $R^{10a}SO_2N(R^{11})C(R^a)(R^b)C(R^c)(R^d)C(=O)$-, and $R^{10a}OC(=O)N(R^{11})C(R^a)(R^b)SO_2$-~~;

R^3 is selected from O and N(R^{13});

R^4 is selected independently at each occurrence form $CR^a(R^b)$, ~~O, N(R^{13}), C(=O), $S(O)_p$,~~ ~~substituted or unsubstituted~~ 3 to 6 membered carbocycle, ~~substituted or unsubstituted~~ 3 to 6 membered heterocycle containing 1 to 2 heteroatom(s) selected from N, S, and O, ~~substituted or unsubstituted~~ 6 membered arylene, and ~~substituted or unsubstituted~~ 5 to 6 membered heteroarylene containing 1 to 2 heteroatom(s) selected from N, S and O, wherein, ~~substitutions on~~said carbocycle, ~~—~~heterocycle,~~—~~ arylene, and

heteroarylene are ~~selected from the group consisting of~~ optionally substituted with halogen, ~~substituted or unsubstituted~~ C_{1-6} alkyl, ~~and~~ or C_{1-6} alkyl-O-;

R^5 is selected from hydrogen and ~~substituted or unsubstituted~~ C_{1-6} alkyl;

R^6 and R^7 are independently selected from the group consisting of hydrogen, halogen, ~~substituted or unsubstituted~~ C_{1-6} alkyl, and $R^{10}O$-;

R^8 is selected from hydrogen and C_{1-6} alkyl;

R^9 is selected from the group consisting of hydrogen, C_{1-6} alkyl, $R^{10a}C(=O)$-, ~~$R^{10a}SO_2$-~~, $R^{10a}OC(=O)$-, $(R^{10})(R^{11})NC(=O)$-, $R^{10a}OC(=O)N(R^{11})CR^aR^bC(=O)$-, and $R^{10a}OC(=O)N(R^{11})CR^aR^bC(R^c)(R^d)C(=O)$-~~, $R^{10}(R^{11})NC(=O)N(R^{12})CR^aR^bC(=O)$-, $R^{10}(R^{11})NC(=O)N(R^{12})CR^aR^bC(R^e)(R^d)C(=O)$-, $R^{10a}SO_2N(R^{11})CR^aR^bC(=O)$-, $R^{10a}SO_2N(R^{11})CR^aR^bC(R^e)(R^d)C(=O)$-, and $R^{10a}OC(=O)N(R^{11})CR^aR^bSO_2$-~~;

R^{10}, R^{11}, R^{11a} and R^{12} are independently selected from hydrogen and ~~substituted or unsubstituted~~ C_{1-6} alkyl;

R^{10a} is ~~substituted or unsubstituted~~ C_{1-6} alkyl;

R^{13} is selected from hydrogen and ~~substituted or unsubstituted~~ C_{1-6} alkyl group;

R^a, R^b, R^c and R^d, are independently selected from hydrogen, halogen, ~~substituted or unsubstituted~~ C_{1-6} alkyl, and ~~substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted~~ C_{3-6} cycloalkyl, ~~and substituted or unsubstituted heterocyclyl,~~ or R^a, R^b, R^c and R^d together with the carbon atom(s) to which they are attached forming ~~substituted or unsubstituted~~ 3 to 6 membered carbocycle, or ~~substituted or unsubstituted~~ 3 to 6 membered heterocycle containing 1 to 2 heteroatom(s) selected from N, S and O;

m is an integer ranging between 0 to 2, selected independently at each occurrence;

n is an integer ranging between 0 and 2;

p is an integer ranging between 0 and 2;

when n = 2 and R^4 is selected as $CR^a(R^b)$ for both the occurrences, two R^as together can form a bond to form a alkenylene linkage or two R^as and two R^bs together can form bonds to form alkynylene linkage.;

~~'alkyl' may be substituted with 1 to 4 substituents selected from the group consisting of oxo, halogen, cyano, aryl, hereroaryl, cycloalkyl, heterocyclyl, (alkyl)C(=O) , (alkyl)SO_2 , $R^{14a}O$, (alkyl)OC(=O) , (alkyl)C(=O)O , (R^{14})(H)NC(=O) , (R^{14})(alkyl)NC(=O) , (alkyl)C(=O)N(H) , R^{14}(H)N , R^{14}(alkyl)N , R^{14}(H)NC(=O)N(H) , and R^{14}(alkyl)NC(=O)N(H) ;~~

~~'cycloalkyl' and 'carbocycle' may be substituted with 1 to 2 substituents selected from the group consisting of oxo, halogen, C_{1-6} alkyl, haloalkyl, (alkyl)C(=O) , (alkyl)SO_2 , $R^{14a}O$, (alkyl)OC(=O) , (alkyl)C(=O)O , R^{14}(H)NC(=O) , R^{14}(alkyl)NC(=O) , (alkyl)C(=O)N(H) , R^{14}(H)N , R^{14}(alkyl)N , R^{14}(H)NC(=O)N(H) , and R^{14}(alkyl)NC(=O)N(H) ;~~

~~'aryl' or 'aromatic carbocycle', may be substituted with 1 to 2 substituents selected from the group consisting of halogen, nitro, cyano, hydroxy, C_1 to C_6 alkyl, perhaloalkyl, alkyl O , perhaloalkyl O , alkyl N(alkyl) , alkyl N(H) , H_2N , alkyl SO_2 , alkyl C(=O)N(alkyl) , alkyl C(=O)N(H) , alkyl N(alkyl)C(=O) , alkyl N(H)C(=O) , $H_2NC(=O)$, alkyl N(alkyl)SO_2 , alkyl N(H)SO_2 , H_2NSO_2 ;~~


~~'heteroaryl' or 'aromatic heterocycle' may be substituted with 1 to 2 substituents selected from the group consisting of halogen, nitro, cyano, hydroxy, C_1 to C_6 alkyl, perhaloalkyl, alkyl O , perhaloalkyl O , alkyl N(alkyl) , alkyl N(H) , H_2N , alkyl SO_2 , alkyl C(=O)N(alkyl) , alkyl C(=O)N(H) , alkyl N(alkyl)C(=O) , alkyl N(H)C(=O) , $H_2NC(=O)$, alkyl N(alkyl)SO_2 , and alkyl N(H)SO_2 , H_2NSO_2 ;~~

~~ring carbons of 'heterocyclyl' and 'heterocycle' may be substituted with 1 to 2 substituents selected from the group consisting of oxo, halogen, alkyl, $R^{14a}O$, (alkyl)OC(=O) , (alkyl)C(=O)O , R^{14}(H)NC(=O) , R^{14}(alkyl)NC(O) , (alkyl)C(=O)N(H) , R^{14}(H)N , R^{14}(alkyl)N , R^{14}(H)NC(=O)N(H) , and R^{14}(alkyl)NC(=O)N(H) ; the substituents on ring nitrogen(s) of 'heterocyclyl' and 'heterocycle' are selected from the group consisting of alkyl, (alkyl)C(=O) , (alkyl)SO_2 , (alkyl)OC(=O) , R^{14}(H)NC(=O) , R^{14}(alkyl)NC(=O) ;~~


~~R^{14} is selected from hydrogen and alkyl;~~

~~R^{14a} is selected from hydrogen, alkyl, perhaloalkyl.~~

2. The compound of formula I or its pharmaceutically acceptable salts, as claimed in claim 1, wherein R^A is selected independently at each occurrence from -




and



,

where, ring A is 3 to 6 membered carbocycle, such that at least once it is selected as



.

3. The compound of formula I or its pharmaceutically acceptable salts, as claimed in any one of claims 1 and 2, wherein R^3 is selected as NH.

4. The compound of formula I or its pharmaceutically acceptable salts, as claimed in any one of claims 1-3, wherein R^4 is selected from phenylene and five membered heteroarylene containing 1 or 2 heteroatoms selected from N and S, when n is selected as 1.



5. The compound of formula I or its pharmaceutically acceptable salts, ~~its clathrates or its co-crystals,~~ as claimed in any one of claims 1-3, wherein R^4 is selected as CR^aR^b, when n is selected as 2 to form an ethylene or ethynylene linkage.


~~**6.** The compound of formula I or its pharmaceutically acceptable salts, as claimed in any one of claims 1-5, wherein n is selected from 0, 1 and 2.~~

~~7.~~6. The compound of formula I or its pharmaceutically acceptable salts, as claimed in any one of claims 1-6, wherein R^5, R^6 and R^7 are selected as hydrogen.

~~8.~~7. The compound of formula I or its pharmaceutically acceptable salts, as claimed in any one of claims 1-6~~7~~, wherein Ring D is selected from the group consisting of 6 membered aromatic carbocycle, six membered carbocycle, seven membered carbocycle, and seven membered heterocycle containing one heteroatom particularly selected as oxygen.

~~9.~~8. The compound of formula I or its pharmaceutically acceptable salts, as claimed in any one of claims 1-7~~8~~, wherein, R^A is selected independently at each occurrence from -


and

,

where, ring A is 3 to 6 membered carbocycle, such that at least once it is selected as  ; R^3 is selected as NH; R^4 is selected from the group consisting of CR^aR^b, phenylene and five membered heteroarylene containing 1 or 2 heteroatoms selected from N and S; n is selected from 0, 1 and 2; R^5, R^6 and R^7 are selected as hydrogen; and Ring D is selected from the group consisting of aromatic carbocycle, six membered carbocycle, seven membered carbocycle, and seven membered heterocycle containing one heteroatom particularly selected as oxygen.

~~10.~~9. The compound of formula I or its pharmaceutically acceptable salts, as claimed in any one of claims 1-8~~9~~, wherein the compound is selected from the group consisting of:

(S)-2-(methoxycarbonyl)amino-N-(1-(6-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-4,5-dihydro-1H-benzo[2,3]oxepino[4,5-d]imidazol-8-yl)-1H-benzo[d]imidazol-2-yl)cyclobutyl)-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(6-(4-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-4,5-dihydro-1H-benzo[2,3]oxepino[4,5-d]imidazol-8-yl)phenyl)-1H-benzo[d]imidazol-2-yl)cyclobutyl)-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(6-(4-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-4,5-dihydro-1H-naphtho[1,2-d]imidazol-7-yl)phenyl)-1H-benzo[d]imidazol-2-yl)cyclobutyl)-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(6-(4-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-1,4,5,6-tetrahydrobenzo[3,4]cyclohepta[1,2-d]imidazol-8-yl)phenyl)-1H-benzo[d]imidazol-2-yl)cyclobutyl)-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(6-(4-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-1H-naphtho[1,2-d]imidazol-7-yl)phenyl)-1H-benzo[d]imidazol-2-yl)cyclobutyl)-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(6-(4-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-4,5-dihydro-1H-benzo[2,3]oxepino[4,5-d]imidazol-8-yl)phenyl)-1H-benzo[d]imidazol-2-yl)cyclopentyl)-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(6-(4-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-1,4,5,6-tetrahydrobenzo[3,4]cyclohepta[1,2-d]imidazol-8-yl)phenyl)-1H-benzo[d]imidazol-2-yl)cyclopentyl)-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(6-(4-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-4,5-

dihydro-1H-naphtho[1,2-d]imidazol-7-yl)phenyl)-1H-benzo[d]imidazol-2-yl)cyclopentyl)-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(6-(4-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-1H-naphtho[1,2-d]imidazol-7-yl)phenyl)-1H-benzo[d]imidazol-2-yl)cyclopentyl)-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(6-(4-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-4,5-dihydro-1H-benzo[2,3]oxepino[4,5-d]imidazol-8-yl)phenyl)-1H-benzo[d]imidazol-2-yl)cyclopropyl)-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(6-(4-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-1,4,5,6-tetrahydrobenzo[3,4]cyclohepta[1,2-d]imidazol-8-yl)phenyl)-1H-benzo[d]imidazol-2-yl)cyclopropyl)-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(6-(4-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-4,5-dihydro-1H-benzo[2,3]oxepino[4,5-d]imidazol-8-yl)phenyl)-1H-benzo[d]imidazol-2-yl)cyclohexyl)-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(6-(4-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-1,4,5,6-tetrahydrobenzo[3,4]cyclohepta[1,2-d]imidazol-8-yl)phenyl)-1H-benzo[d]imidazol-2-yl)cyclohexyl)-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(6-(4-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-1H-naphtho[1,2-d]imidazol-7-yl)phenyl)-1H-benzo[d]imidazol-2-yl)cyclohexyl)-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(6-(4-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-4,5-dihydro-1H-naphtho[1,2-d]imidazol-7-yl)phenyl)-1H-benzo[d]imidazol-2-yl)cyclohexyl)-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(6-(4-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-4,5-dihydro-1H-naphtho[1,2-d]imidazol-7-yl)phenyl)-1H-benzo[d]imidazol-2-yl)cyclobutyl)-N-ethyl-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(6-(4-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-4,5-dihydro-1H-naphtho[1,2-d]imidazol-7-yl)phenyl)-1H-benzo[d]imidazol-2-yl)cyclobutyl)-N,3-dimethylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(6-(4-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-1H-naphtho[1,2-d]imidazol-7-yl)phenyl)-1H-benzo[d]imidazol-2-yl)cyclobutyl)-N,3-dimethylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(8-(4-(2-(1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanamido)cyclopentyl)-1H-benzo[d]imidazol-6-yl)phenyl)-4,5-dihydro-1H-benzo[2,3]oxepino[4,5-d]imidazol-2-yl)cyclopentyl)-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(6-(4-(2-(1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanamido)cyclohexyl)-4,5-dihydro-1H-benzo[2,3]oxepino[4,5-d]imidazol-8-yl)phenyl)-1H-benzo[d]imidazol-2-yl)cyclopentyl)-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(8-(4-(2-(1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanamido)cyclohexyl)-1H-benzo[d]imidazol-6-yl)phenyl)-4,5-dihydro-1H-benzo[2,3]oxepino[4,5-d]imidazol-2-yl)cyclohexyl)-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(8-(4-(2-(1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanamido)cyclohexyl)-1H-benzo[d]imidazol-6-yl)phenyl)-4,5-dihydro-1H-benzo[2,3]oxepino[4,5-d]imidazol-2-yl)cyclopentyl)-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(6-(5-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-1H-

naphtho[1,2-d]imidazol-7-yl)thiophen-2-yl)-1H-benzo[d]imidazol-2-yl)cyclobutyl)-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(6-(5-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-4,5-dihydro-1H-naphtho[1,2-d]imidazol-7-yl)thiophen-2-yl)-1H-benzo[d]imidazol-2-yl)cyclohexyl)-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(6-((2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-4,5-dihydro-1H-naphtho[1,2-d]imidazol-7-yl)ethynyl)-1H-benzo[d]imidazol-2-yl)cyclohexyl)-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(6-(2-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-4,5-dihydro-1H-naphtho[1,2-d]imidazol-7-yl)ethyl)-1H-benzo[d]imidazol-2-yl)cyclohexyl)-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(5-(5-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-4,5-dihydro-1H-benzo[2,3]oxepino[4,5-d]imidazol-8-yl)thiazol-2-yl)-1H-benzo[d]imidazol-2-yl)cyclohexyl)-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(8-(4-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-1H-benzo[d]imidazol-6-yl)phenyl)-4,5-dihydro-1H-benzo[2,3]oxepino[4,5-d]imidazol-2-yl)cyclopentyl)-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(8-(4-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-1H-benzo[d]imidazol-6-yl)phenyl)-4,5-dihydro-1H-benzo[2,3]oxepino[4,5-d]imidazol-2-yl)cyclohexyl)-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(7-(4-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-1H-benzo[d]imidazol-6-yl)phenyl)-4,5-dihydro-1H-naphtho[1,2-d]imidazol-2-yl)cyclobutyl)-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(7-(4-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-1H-benzo[d]imidazol-6-yl)phenyl)-1H-naphtho[1,2-d]imidazol-2-yl)cyclobutyl)-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(7-(4-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-1H-benzo[d]imidazol-6-yl)phenyl)-4,5-dihydro-1H-naphtho[1,2-d]imidazol-2-yl)cyclohexyl)-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(7-(4-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-1H-benzo[d]imidazol-6-yl)phenyl)-1H-naphtho[1,2-d]imidazol-2-yl)cyclohexyl)-3-methylbutanamide; and

(S)-2-(methoxycarbonyl)amino-N-(1-(8-(4-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-1H-benzo[d]imidazol-6-yl)phenyl)-4,5-dihydro-1H-benzo[2,3]oxepino[4,5-d]imidazol-2-yl)cyclobutyl)-3-methylbutanamide.

~~11.~~10. A pharmaceutical composition comprising a compound or a combination of compounds according to any one of claims 1-9~~10~~ or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier or excipient.

~~12.~~11. A pharmaceutical composition ~~to inhibit the replication of an RNA-containing virus comprising contacting said virus with~~comprising a therapeutically effective amount of a compound or combination of compounds of any one of claims 1-9~~10~~, or a pharmaceutically acceptable salt thereof for use in inhibiting the replication of an RNA-containing virus.

~~13.~~12. A pharmaceutical composition ~~for treating or preventing infection caused by an RNA-containing virus comprising administering to a patient in need of such treatment~~ comprising a therapeutically effective amount of a compound or combination of compounds of any one of claims 1-9~~10~~, or a pharmaceutically acceptable salt thereof for use in treating or preventing infection caused by an RNA-containing virus.

~~14.~~13. The therapeutical effective amount of the pharmaceutical composition for use according to ~~in~~ claim 11~~2~~, wherein the RNA-containing virus is hepatitis C virus.

~~15.~~14. The use according to claim 11~~2~~, further comprising the step of co-administering one or more agents selected from the group consisting of a host immune modulator and an antiviral agent, or a combination thereof.

~~16.~~15. The use of claim 13~~4~~, wherein the host immune modulator is selected from the group consisting of interferon-alpha, pegylated-interferon-alpha, interferon-beta, interferon-gamma, consensus interferon, a cytokine, and a vaccine.

~~17.~~16. The use of claim 13~~4~~, wherein the antiviral agent inhibits replication of HCV by inhibiting host cellular functions associated with viral replication.

~~18.~~17. The use of claim 13~~4~~, wherein the antiviral agent inhibits the replication of HCV by targeting proteins of the viral genome.

~~19.~~18. The use of claim 13~~4~~, wherein said antiviral agent is an inhibitor of a HCV viral protein, a replication process or a combination thereof, wherein said targeting protein or replication process is selected from the group consisting of helicase, protease, polymerase, metalloprotease, NS4A, NS4B, NS5A, assembly, entry, and IRES.

~~20.~~19. The use of claim 11~~2~~, further comprising the step of co-administering an agent or combination of agents that treat or alleviate symptoms of HCV infection selected from cirrhosis and inflammation of the liver.

~~21.~~20. The use of claim 11~~2~~, further comprising the step of co-administering one or more agents that treat patients for disease caused by hepatitis B (HBV) infection.

~~22.~~21. The use of claim 11~~2~~, further comprising the step of co-administering one or more agents that treat patients for disease caused by human immunodeficiency virus (HIV) infection.

~~23.~~22. The pharmaceutical composition of claim 10~~1~~, further comprising an agent selected from interferon, pegylated interferon, ribavirin, amantadine,

an HCV protease inhibitor, an HCV polymerase inhibitor, an HCV helicase inhibitor, or an internal ribosome entry site inhibitor.

~~24.~~23. The composition of claim 10~~1~~, further comprising a cytochrome P450 monooxygenase inhibitor or a pharmaceutically acceptable salt thereof.

~~25.~~24. A pharmaceutical composition comprising ~~for treating hepatitis C infection in a subject in need thereof comprising co-administering to said subject~~ a cytochrome P450 monooxygenase inhibitor or a pharmaceutically acceptable salt thereof, and a compound of any one of claims 1-9~~10~~ or a pharmaceutically acceptable salt thereof for treating hepatitis C infection.